Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL01211 in Treatment-Naïve Classic Fabry Disease
NCT06114329Phase 2Recruiting
- Sponsor
- AceLink Therapeutics
- Start
- Oct 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of AL01211 in Fabry disease (FD) (2 arms), sponsored by AceLink Therapeutics. Primary endpoint: Treatment-emergent adverse events at 104 weeks. Started Oct 2023; status: recruiting.
02
Drugs
AL01211
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT06114329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06114329.